Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease
Intramuscular injections are contra-indicated in infants with either acquired or congenital bleeding disorders. In such patients, it is unlicensed practice to administer vaccines by subcutaneous route. However, there are no reports on subcutaneous administration of palivizumab (Synagis®). We report...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Hygeia Press di Corridori Marinella,
2015-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |